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Outpatient tested positive for SARS-CoV-2 infection 
(removed as the outcome was uncertain) 
 
n = 614 (0.1%) 
Participants from Scotland and Wales  
(removed as testing was only available in England) 
n = 56,649 (11.3%) 
Participants who died before the first testing for SARS-CoV-2 infection (16 March 2020) 
n = 25,306 (5.0%) 
Participants with missing factor data 
Ethnicity = 2,416 
Deprivation = 528 
Body mass index = 2,469; underweight = 2,093 
Smoke = 2,492 
Air pollution = 4,892 
25(OH) D concentration level = 45,934 
Walking pace = 3,620 
C-reactive protein = 29,265 
 
Participants may have more than one factor missing 
 
 
n = 59,685 (11.9 %) 
Main analysis: complete case 
 
N = 360,283 (71.7 %) 
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Table S1: Literature search on the most common pre-existing comorbidities in patients with severe SARS-CoV-2 infection 
 
Reference Type of study and date Study population 
 
Most common pre-existing comorbidities associated 
with patients with severe SARS-CoV-2 infection 
(hospitalised) 
 
Arentz et al, 2020 [1] 
Case series 
February 20 to March 5, 2020 
21 critically ill patients with COVID-
19 in Washington State, United 
States 
 
1. Chronic kidney disease  
2. Heart failure 
3. Diabetes 
4. Chronic obstructive pulmonary disease  
5. Obstructive sleep apnoea 
6. Asthma 
Du et al. 2020 [2] 
Prospective cohort study, 
25 December 2019, to 7 February 2020 
179 patients who were hospitalised 
with COVID-19 to Wuhan 
Pulmonary Hospital, China 
 
1. Hypertension  
2. Diabetes mellitus 
3. Cardiovascular or cerebrovascular diseases 
4. Chronic digestive disorders 
5. Tuberculosis 
6. Cancer, malignancy 
7. Peripheral vascular disease  
Emami et al. 2020 [3] 
Systematic review and meta-analysis 
Until 15 February 2020 
10 articles  
3,403 hospitalised patients with 
COVID-19 
 
1. Hypertension  
2. Cardiovascular diseases 
3. Diabetes mellitus 
4. Chronic obstructive pulmonary disease  
5. Cancer, malignancy 
6. Chronic kidney disease  
Grasselli et al, 2020 [4] 
Retrospective case series 
February 20 to March 18 2020 
1591 critically ill patients admitted to 
ICUs in Lombardy, Italy 
 
1. Hypertension 
2. Cardiovascular disease 
3. Hypercholesterolemia 
4. Diabetes, type 2 
5. Cancer, malignancy 
6. Chronic obstructive pulmonary disease  
7. Chronic liver disease 
8. Chronic kidney disease  
 Guan et al. 2020 [5] 
Retrospective case study, 
11 December 2019, to 31 January 2020 
1590 laboratory confirmed 
hospitalised patients from 575 
hospitals in 31 
provinces/autonomous 
regions/provincial municipalities 
across mainland China 
 
1. Hypertension  
2. Cardiovascular or cerebrovascular diseases 
3. Diabetes mellitus 
4. Hepatitis B infection 
5. Chronic kidney disease 
6. Cancer, malignancy 
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Reference Type of study and date Study population 
 
Most common pre-existing comorbidities associated 
with patients with severe SARS-CoV-2 infection 
(hospitalised) 
 
Ji et al, 2020 [6] 
Nationwide retrospective case-control 
study 
Until May 15 2020 
Severe cases were 954 of 7,341, 
Korea  
1. Hypertension  
2. Diabetes mellitus 
3. Chronic lower respiratory disease 
4. Chronic renal failure 
Li X et al, 2020 [7] 
 
Retrospective study  
January 26 to February 5 2020 
548 patients as severe cases on 





4. Coronary heart disease 
5. Tuberculosis  
6. Chronic obstructive pulmonary disease  
7. Cancer, tumour 
8. Chronic kidney disease  
9. Hepatitis B 
 
Myers et al. 2020 [8] 
Retrospective cohort study, 
March 1 2020, to March 31 2020 
377 were treated as inpatients and 
113 were treated in the ICU, in 21 
hospitals, California, United States 
1. Hypertension  
2. Diabetes mellitus 
3. Chronic kidney disease  
4. Chronic obstructive pulmonary disease or asthma 
5. Heart failure 
6. Liver cirrhosis 
7. Cancer, malignancy 
Petrilli et al, 2020 [9] 
Prospective cohort study 
1 March 2020 and 8 April 2020 
2741 were admitted to hospital, New 




2. Cardiovascular disease 
3. Asthma or chronic obstructive pulmonary disease  
4. Diabetes  
5. Cancer 
6. Chronic kidney disease  
 
Q et al. 2020 [10] 
Retrospective cohort study, 
January 30 2020, to February 11 2020 
108 adult patients with 
COVID‑19 were hospitalised in the 
Dabieshan Medical Center, 
Huanggang, China 
 
1. Hypertension  
2. Diabetes mellitus 
3. Chronic obstructive pulmonary disease  
4. Cardiovascular disease 
5. Chronic liver disease 
6. Cancer 
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Reference Type of study and date Study population 
 
Most common pre-existing comorbidities associated 
with patients with severe SARS-CoV-2 infection 
(hospitalised) 
 
Richardson et al. 2020 
[11] 
Case series,  
March 1 2020, to April 4 2020 
5,700 hospitalised patients with 
COVID-19, in 12 hospitals across 
New York, United States 
 
1. Hypertension 
2. Cardiovascular disease 
3. Obesity 
4. Diabetes mellitus 
5. Cancer 
 
Yang J et al, 2020 [12] 
Systematic review and meta-analysis 
Until 25 February 2020 
7 articles 
1,576 infected patients from 
hospitals in China 
1. Hypertension  
2. Diabetes mellitus 
3. Respiratory system disease 
4. Cardiovascular disease 
 
Yang X et al. 2020 [13] 
Retrospective study 
Before 31 January 2020 
52 critically ill adult patients with 
SARS-CoV-2 pneumonia who were 
admitted to the intensive care unit of 
Wuhan Jin Yin-tan hospital, 
China 
 
1. Cerebrovascular disease  
2. Diabetes mellitus 
3. Chronic cardiac disease 
4. Chronic pulmonary disease  
 
 
Zhou et al. 2020 [14] 
Retrospective, multicentre cohort study 
Before 31 January 2020 
191 patients with COVID-19 (135 
from Jinyintan Hospital and 56 from 
Wuhan Pulmonary Hospital), China 
1. Hypertension  
2. Diabetes mellitus 
3. Coronary heart disease 
4. Chronic obstructive lung disease  
5. Cancer, Carcinoma 
6. Chronic kidney disease  
 
 
Google Scholar and PubMed searches for studies in published in English were carried out with the terms “comorbidity”; “severe SARS-CoV-2”; or 
“COVID-19 hospitalisation” on 3rd July 2020.  In the table we reported the studies we deemed most relevant. We did not include studies that were 
already considered in the systematic reviews.
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Table S2. Association between multimorbidity index using 3 or more conditions and risk of severe 
SARS-CoV-2 infection 
 
Odds ratios comparing subjects with multimorbidity (≥3 conditions) vs without multimorbidity (reference: <3 conditions). P-values tested 
for interaction. 
 
OR=odds ratio; CI=confidence interval; NO2=nitrogen dioxide. 
 
Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25‑hydroxyvitamin D, 
cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of vitamin D supplement. 
Risk of severe SARS-CoV-2 infection  
(hospitalisation or death) 
OR (95% CI)  
 
P-value 
Age at test 
< 60 years (n=83,269) 2.01 (0.73, 5.52) 
0.790 
 60 years (n=277,014) 2.00 (1.66, 2.42) 
Sex 
Women (n=195,571) 1.81 (1.28, 2.57) 
0.106 
Men (n=164,712) 2.03 (1.63, 2.53) 
Ethnicity 
White (n=340,619) 1.94 (1.60, 2.36) 
0.330 
Non-white (n=19,664) 2.75 (1.60, 4.72) 
Deprivation 
Least deprived (n=180,147) 2.65 (1.98, 3.56) 
0.070 
Most deprived (n=180,136) 1.72 (1.36, 2.18) 
Body mass index 
Normal (n=120,764) 1.13 (0.55, 2.30) 
0.340 Overweight (n=153,914) 2.25 (1.67, 3.04) 
Obese (n=85,605) 2.05 (1.59, 2.62) 
Smoke 
Never (n=200,669) 2.06 (1.49, 2.83) 
0.577 Previous (n=124,882) 2.00 (1.56, 2.56) 
Current (n=34,732) 1.71 (1.00, 2.92) 
Air pollution (NO2) 
Low/moderate level (n=335,378) 2.00 (1.64, 2.43) 
0.467 
High level (n=24,905) 2.12 (1.25, 3.60) 
25‑hydroxyvitamin D levels  
Severe deficiency (n=43,558) 1.22 (0.76, 1.95) 
0.036 
Sufficient (n=316,725) 2.24 (1.84, 2.74) 
Cardiorespiratory fitness 
Slow walking pace (n=25,569) 2.00 (1.51, 2.64) 
0.772 
Steady-brisk walking pace (n=334,714) 1.98 (1.55, 2.54) 
C-reactive protein level 
Normal (n=282,720) 2.24 (1.78  2.81) 
0.121 
High (n=77,563) 1.68 (1.23, 2.30) 
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Odds ratios comparing subjects with multimorbidity vs without multimorbidity (reference). 
 
OR=odds ratio; CI=confidence interval; NO2=nitrogen dioxide. 
 
Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25‑
hydroxyvitamin D, cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of Vitamin D 
supplement. 
 
* Model adjusted for regular intake of Vitamin D supplement at follow-up, the season of blood draw was not known at 
follow-up. 
Risk of severe SARS-CoV-2 
infection ( hospitalisation or 
death) 
  OR (95% CI) 
2 or more pre-existing 
multimorbidity index conditions 
3 or more pre-existing multimorbidity 
index conditions 
25‑hydroxyvitamin D levels categories  
<25 nmol/L (n=43,558) 1.80 (1.36, 2.37) 1.22 (0.76, 1.94) 
25-50 nmol/L (n=148,624) 2.01 (1.69, 2.40) 2.09 (1.59, 2.75) 
50-75 nmol/L (n=125,430) 1.84 (1.47, 2.30) 2.71 (1.94, 3.80) 
75 nmol/L (n=42,671) 1.81 (1.27, 2.58) 1.76 (0.96, 3.23) 
25‑hydroxyvitamin D levels at follow-up * 
Severe deficiency (n=2,165) 2.30 (0.75, 7.11) 1.21 (0.14, 10.36) 
Sufficient (n=12,376) 3.14 (1.67, 5.93) 2.92 (0.99, 8.56) 
Air pollution (NO2) last recorded 
Low-moderate level (n=344,059) 1.93 (1.71, 2.17) 2.08 (1.72, 2.52) 
High level (n=16,224) 1.66 (1.03, 2.68) 1.25 (0.58, 2.69) 
Air pollution (PM 2.5) last recorded 
Low-moderate level (n=192,392) 2.08 (1.75, 2.46) 2.50 (1.92, 3.25) 
High level (n=167,891) 1.78 (1.51, 2.08) 1.68 (1.30, 2.18) 
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Table S4. Sensitivity analyses considering time in the study and removing 
cardiorespiratory fitness and C-reactive protein from the model 
 
 
Odds ratios comparing subjects with multimorbidity vs without multimorbidity (reference).  
 
OR=odds ratio; CI=confidence interval.  
 
Unless stated the models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air 
pollution, 25‑hydroxyvitamin D, cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of 
Vitamin D supplement. 
 
* Time in the study was calculated from the date of the baseline characteristics collection to the date of hospitalisation of 
SARS-CoV-2, date of mortality or date of last censoring in the study. 
Risk of severe SARS-CoV-2 
infection (hospitalisation or 
death) 
  OR (95% CI) 
2 or more pre-existing 
multimorbidity index conditions 
3 or more pre-existing 
multimorbidity index conditions 
Additionally adjusted for 
time in the study * 
1.91 (1.70, 2.15) 2.02 (1.68, 2.43) 
Removal of cardiorespiratory 
fitness, C-reactive protein 
2.09 (1.87, 2.35) 2.40 (2.00, 2.87) 
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Checklist S1. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
 
 
 Item No Recommendation  
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Title and abstract 
(b) Provide in the abstract an informative and balanced summary of what was done and 
what was found 
Abstract, methods and 
findings 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Introduction paragraph 1-3 
Objectives 3 State specific objectives, including any prespecified hypotheses Introduction paragraph 4 
Methods  
Study design 4 Present key elements of study design early in the paper Methods, Study Population 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Methods, Study Population 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Methods, Study Population 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Methods, Multimorbidity 
index, Outcome measures, 
Effect modifiers 
Data sources/ measurement 8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
Methods, Multimorbidity 
index, Outcome measures, 
Effect modifiers 
Bias 9 Describe any efforts to address potential sources of bias Methods, Study Population, 
Statistical Analysis 
paragraph 3 
Study size 10 Explain how the study size was arrived at Supporting Information,  
Figure S1 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Methods, Multimorbidity 
index, Effect modifiers, 
Statistical analysis 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Methods, Statistical analysis 
(b) Describe any methods used to examine subgroups and interactions NA 
(c) Explain how missing data were addressed Methods, Statistical analysis 
paragraph 1 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed NA 




Participants 13* (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and 
analysed 
Methods, Study Population 
(b) Give reasons for non-participation at each stage Methods, Study Population 
(c) Consider use of a flow diagram Supporting Information, 
Figure S1  
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, social) and 
information on exposures and potential confounders 
Results, Participant 
Characteristics  
(b) Indicate number of participants with missing data for each variable of interest Supporting Information 
Figure S1  
(c) Cohort study—Summarise follow-up time (e.g., average and total amount) NA 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Results, Participant 
Characteristics, Pattern of 
multimorbidity  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
Results, Risk of severe 
SARS-CoV-2 infection 
(b) Report category boundaries when continuous variables were categorized Results, Risk of severe 
SARS-CoV-2 infection 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
NA 
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity 
analyses 




Key results 18 Summarise key results with reference to study objectives Discussion paragraph 1 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias 
Discussion paragraph 5 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Discussion paragraph 2-5 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion paragraph 6 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based. 
End of the manuscript 
 
 
 
